Better Identification of Cognitive Decline With Interleukin-2 Than With Amyloid and Tau Protein Biomarkers in Amnestic Mild Cognitive Impairment.

Frontiers in Aging Neuroscience
Chih-Sung LiangFu-Chi Yang

Abstract

The rate of cognitive decline among patients with amnestic mild cognitive impairment (aMCI) varies, and it is thus crucial to accurately predict the probability of cognitive deterioration in patients with MCI. We compared the potential of cytokines with amyloid beta (Aβ) and tau biomarkers for predicting cognitive decline in patients with aMCI or Alzheimer's disease (AD). All participants (controls, aMCI, and AD patients) underwent plasma biomarker examinations for Aβ1-40, Aβ1-42, total tau (t-tau), tau phosphorylated at threonine 181 [p-Tau181]), and 29 cytokines and baseline cognitive tests, including Mini-Mental State Examination (MMSE). The correlation between biomarker levels and annual MMSE change during the follow-up was examined. Receiver operating characteristic (ROC) curve analysis was performed to determine whether the statistically significant plasma biomarkers could identify cognitive decline. Higher baseline levels of IL-2, sCD40L, IL-8, and VEGF were associated with a lower annual cognitive decline in the aMCI group, and higher baseline levels of Aβ1-40, IFNγ, IL-5, IL-17A, IL-25, and FGF were associated with a rapid annual cognitive decline in the AD group. IL-2 had a high discriminatory capacity for identifying...Continue Reading

References

Jul 22, 2004·Brain, Behavior, and Immunity·William A BanksSteven S Zalcman
Dec 17, 2009·Archives of Neurology·Ronald C PetersenClifford R Jack
Jun 10, 2011·The New England Journal of Medicine·Ronald C Petersen
Mar 19, 2013·Alzheimer's Research & Therapy·Curtis TatsuokaUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Dec 17, 2014·JAMA : the Journal of the American Medical Association·Kenneth M Langa, Deborah A Levine
Mar 21, 2015·Lancet Neurology·Michael T HenekaMarkus P Kummer
May 21, 2015·Nature Reviews. Neuroscience·Frank L HeppnerBurkhard Becher
Feb 26, 2016·Brain : a Journal of Neurology·Cira DansokhoGuillaume Dorothée
Dec 19, 2017·Journal of Neurology, Neurosurgery, and Psychiatry·Eleanor KingAlan J Thomas
Feb 9, 2018·Nature·Akinori NakamuraKatsuhiko Yanagisawa
Apr 8, 2018·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Michelle M MielkeJeffrey L Dage
Apr 15, 2018·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Clifford R JackUNKNOWN Contributors
Jan 12, 2019·Journal of Neurology, Neurosurgery, and Psychiatry·Xue-Ning ShenJin-Tai Yu
May 3, 2019·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Angharad R MorganUNKNOWN Annex: NIMA–Wellcome Trust Consortium for Neuroimmunology of Mood Disorders and Alzheimer's Disease
Sep 5, 2019·Frontiers in Aging Neuroscience·Seun JeonYoung Noh
Jul 10, 2020·Human Brain Mapping·Sebastian G PopescuUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Jul 18, 2020·Alzheimer's Research & Therapy·Chih-Sung LiangFu-Chi Yang
Oct 28, 2020·Molecular Psychiatry·Thomas K KarikariUNKNOWN Alzheimer’s Disease Neuroimaging Initiative
Jan 12, 2021·JAMA Neurology·Alexis MoscosoUNKNOWN Alzheimer’s Disease Neuroimaging Initiative

❮ Previous
Next ❯

Software Mentioned

SPSS
Plex Manager
Bio

Related Concepts

Related Feeds

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.